Revance Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	9.79	13.23	0.14	0.02
Research & Development	3.75	3.48	0.97	0.49
Operating Expenses	13.57	16.73	1.12	0.52
Operating Income	-13.57	-16.73	-1.12	-0.52
Interest Expense	-7.94	-6.62	-	-
Interest & Investment Income	0.02	0.05	0	-
Other Non Operating Income (Expenses)	-0.54	-15.67	-	0.1
EBT Excluding Unusual Items	-22.03	-38.98	-1.12	-0.42
Other Unusual Items	49.56	47.93	0.7	-
Pretax Income	27.53	8.95	-0.42	-0.42
Net Income	27.53	8.95	-0.42	-0.42
Net Income to Common	27.53	8.95	-0.42	-0.42
Shares Outstanding (Basic)	14	8	3	7
Shares Outstanding (Diluted)	19	12	3	7
Shares Change (YoY)	559.35%	287.55%	-54.84%	-
EPS (Basic)	2.03	1.07	-0.14	-0.06
EPS (Diluted)	1.44	0.75	-0.14	-0.06
Free Cash Flow	-9.21	-7.44	-0.37	-0.46
Free Cash Flow Per Share	-0.48	-0.63	-0.12	-0.07
EBITDA	-13.54	-16.71	-1.11	-0.51
D&A For EBITDA	0.03	0.02	0.01	0
EBIT	-13.57	-16.73	-1.12	-0.52

Updated Aug 20, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.